CRISPR Gnome Editing MIT Technology Review Article (Summarized by TextSum)

Last year, a New Zealand woman became the first to receive a gene-editing treatment to permanently lower her cholesterol.The cholesterol-lowering treatment, developed by Verve Therapeutics, relies on a form of gene editing called base editing, or “CRISPR 2.0.”

It’s a more targeted approach—instead of simply making cuts to shut off specific genes, scientists can now swap a single DNA base for another. Together, these newer forms of CRISPR could broaden the scope of gene editing to take on many conditions—not all of them genetic.

Someday, people may have the option to add genes thought to protect against high blood pressure or certain diseases, to their genetic code.

Disclaimer: This post is a condensed form of the original post generated by the text summarization tool TextSum developed by me. This post is just for the purpose of spreading knowledge and no other purpose. The uncondensed form of the article can be read at MIT Technilogy Review page.